Strober, B., Gottlieb, A., van de Kerkhof, P., Puig, L., Bachelez, H., Chouela, E., . . . Wolk, R. (2018). Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: Pooled analysis across six clinical trials. Br J Dermatol.
Chicago Style CitationStrober, B.E., et al. "Benefit–risk Profile of Tofacitinib in Patients With Moderate‐to‐severe Chronic Plaque Psoriasis: Pooled Analysis Across Six Clinical Trials." Br J Dermatol 2018.
Cita MLAStrober, B.E., et al. "Benefit–risk Profile of Tofacitinib in Patients With Moderate‐to‐severe Chronic Plaque Psoriasis: Pooled Analysis Across Six Clinical Trials." Br J Dermatol 2018.
Atenció: Aquestes cites poden no estar 100% correctes.